Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $30.00 Consensus Target Price from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given an average rating of "Buy" by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $30.00.

A number of equities analysts recently commented on ATXS shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Friday.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors have recently bought and sold shares of ATXS. KLP Kapitalforvaltning AS purchased a new position in Astria Therapeutics during the fourth quarter worth about $41,000. GAMMA Investing LLC grew its position in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after buying an additional 7,971 shares during the period. Brooklyn Investment Group increased its holdings in Astria Therapeutics by 1,079.6% in the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company's stock valued at $46,000 after buying an additional 7,957 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 2,766 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $50,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Up 1.2%

NASDAQ:ATXS traded up $0.07 on Thursday, reaching $5.67. 212,363 shares of the company's stock were exchanged, compared to its average volume of 387,524. The firm has a market capitalization of $319.70 million, a price-to-earnings ratio of -2.71 and a beta of 0.39. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $12.92. The business has a fifty day moving average of $4.57 and a 200-day moving average of $6.62.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10). As a group, equities analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.